RaGE-mediated suppression of interleukin-10 results in enhanced mortality in a murine model of acinetobacter baumannii sepsis

Infection and Immunity

Volumn 85, Issue 3, 2017, Pages

  Noto, Michael J ^a   Becker, Kyle W ^a   Boyd, Kelli L ^a   Schmidt, Ann Marie ^b   Skaar, Eric P ^a,c  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^c DEPARTMENT OF VETERANS AFFAIRS   (United States)

Author keywords

Acinetobacter baumannii; IL 10; Innate immunity; Pneumonia; RAGE; Receptor for advanced glycation end products; Sepsis

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; INTERLEUKIN 10;

ACINETOBACTER BAUMANNII; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL LOAD; BACTERIAL PNEUMONIA; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; HOST PATHOGEN INTERACTION; LIVER; MORTALITY; MOUSE; NONHUMAN; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; SEPSIS; SIGNAL TRANSDUCTION; SPLEEN; ACINETOBACTER INFECTION; ANIMAL; BIOSYNTHESIS; DISEASE MODEL; GENETICS; IMMUNOLOGY; INNATE IMMUNITY; KAPLAN MEIER METHOD; KNOCKOUT MOUSE; LEUKOCYTE COUNT; METABOLISM; MICROBIOLOGY; PHYSIOLOGY; SEVERITY OF ILLNESS INDEX;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ADVANCED GLYCOSYLATION END PRODUCT-SPECIFIC RECEPTOR; ANIMALS; DISEASE MODELS, ANIMAL; FEMALE; IMMUNITY, INNATE; INTERLEUKIN-10; KAPLAN-MEIER ESTIMATE; LEUKOCYTE COUNT; MICE; MICE, KNOCKOUT; SEPSIS; SEVERITY OF ILLNESS INDEX; SIGNAL TRANSDUCTION;

EID: 85014092016     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.00954-16     Document Type: Article

References (50)

1. Barton GM. 2008. A calculated response: control of inflammation by the innate immune system. J Clin Invest 118:413- 420. https://doi.org/ 10.1172/JCI34431.
2. Barton GM, Kagan JC. 2009. A cell biological view of Toll-like receptor function: regulation through compartmentalization. Nat Rev Immunol 9:535-542. https://doi.org/10.1038/nri2587.
3. Di Gioia M, Zanoni I. 2015. Toll-like receptor co-receptors as master regulators of the immune response. Mol Immunol 63:143-152. https:// doi.org/10.1016/j.molimm.2014.05.008.
4. Weighardt H, Holzmann B. 2007. Role of Toll-like receptor responses for sepsis pathogenesis. Immunobiology 212:715-722. https://doi.org/ 10.1016/j.imbio.2007.09.010.
5. Hotchkiss RS, Karl IE. 2003. The pathophysiology and treatment of sepsis. N Engl J Med 348:138 -150. https://doi.org/10.1056/NEJMra021333.
6. Bierhaus A, Humpert PM, Morcos M, Wendt T, Chavakis T, Arnold B, Stern DM, Nawroth PP. 2005. Understanding RAGE, the receptor for advanced glycation end products. J Mol Med (Berl) 83:876-886. https://doi.org/ 10.1007/s00109-005-0688-7.
7. Chuah YK, Basir R, Talib H, Tie TH, Nordin N. 2013. Receptor for advanced glycation end products and its involvement in inflammatory diseases. Int J Inflam 2013:403460. https://doi.org/10.1155/2013/403460.
8. Park H, Adsit FG, Boyington JC. 2010. The 1.5 A crystal structure of human receptor for advanced glycation endproducts (RAGE) ectodomains reveals unique features determining ligand binding. J Biol Chem 285:40762-40770. https://doi.org/10.1074/jbc.M110.169276.
9. Yeh CH, Sturgis L, Haidacher J, Zhang XN, Sherwood SJ, Bjercke RJ, Juhasz O, Crow MT, Tilton RG, Denner L. 2001. Requirement for p38 and p44/p42 mitogen-activated protein kinases in RAGE-mediated nuclear factor-kappaB transcriptional activation and cytokine secretion. Diabetes 50:1495-1504. https://doi.org/10.2337/diabetes.50.6.1495.
10. Hermani A, De Servi B, Medunjanin S, Tessier PA, Mayer D. 2006. S100A8 and S100A9 activate MAP kinase and NF-kappaB signaling pathways and trigger translocation of RAGE in human prostate cancer cells. Exp Cell Res 312:184 -197. https://doi.org/10.1016/j.yexcr.2005.10.013.
11. Huttunen HJ, Fages C, Rauvala H. 1999. Receptor for advanced glycation end products (RAGE)-mediated neurite outgrowth and activation of NF-kappaB require the cytoplasmic domain of the receptor but different downstream signaling pathways. J Biol Chem 274:19919-19924. https:// doi.org/10.1074/jbc.274.28.19919.
12. Lander HM, Tauras JM, Ogiste JS, Hori O, Moss RA, Schmidt AM. 1997. Activation of the receptor for advanced glycation end products triggers a p21(ras)-dependent mitogen-activated protein kinase pathway regulated by oxidant stress. J Biol Chem 272:17810-17814. https://doi.org/ 10.1074/jbc.272.28.17810.
13. Zong H, Madden A, Ward M, Mooney MH, Elliott CT, Stitt AW. 2010. Homodimerization is essential for the receptor for advanced glycation end products (RAGE)-mediated signal transduction. J Biol Chem 285: 23137-23146. https://doi.org/10.1074/jbc.M110.133827.
14. Tanaka N, Yonekura H, Yamagishi S, Fujimori H, Yamamoto Y, Yamamoto H. 2000. The receptor for advanced glycation end products is induced by the glycation products themselves and tumor necrosis factor-alpha through nuclear factor-kappa B, and by 17beta-estradiol through Sp-1 in human vascular endothelial cells. J Biol Chem 275:25781-25790. https:// doi.org/10.1074/jbc.M001235200.
15. Bierhaus A, Schiekofer S, Schwaninger M, Andrassy M, Humpert PM, Chen J, Hong M, Luther T, Henle T, Kloting I, Morcos M, Hofmann M, Tritschler H, Weigle B, Kasper M, Smith M, Perry G, Schmidt AM, Stern DM, Haring HU, Schleicher E, Nawroth PP. 2001. Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB. Diabetes 50:2792-2808. https://doi.org/10.2337/diabetes.50.12.2792.
16. Achouiti A, de Vos AF, van 't Veer C, Florquin S, Tanck MW, Nawroth PP, Bierhaus A, van der Poll T, van Zoelen MA. 2016. Receptor for advanced glycation end products (RAGE) serves a protective role during Klebsiella pneumoniae-induced pneumonia. PLoS One 11:e0141000. https:// doi.org/10.1371/journal.pone.0141000.
17. Christaki E, Opal SM, Keith JC, Jr, Kessimian N, Palardy JE, Parejo NA, Tan XY, Piche-Nicholas N, Tchistiakova L, Vlasuk GP, Shields KM, Feldman JL, Lavallie ER, Arai M, Mounts W, Pittman DD. 2011. A monoclonal antibody against RAGE alters gene expression and is protective in experimental models of sepsis and pneumococcal pneumonia. Shock 35:492- 498. https://doi.org/10.1097/SHK.0b013e31820b2e1c.
18. van Zoelen MA, Schouten M, de Vos AF, Florquin S, Meijers JC, Nawroth PP, Bierhaus A, van der Poll T. 2009. The receptor for advanced glycation end products impairs host defense in pneumococcal pneumonia. J Immunol 182:4349-4356. https://doi.org/10.4049/jimmunol.0801199.
19. Liliensiek B, Weigand MA, Bierhaus A, Nicklas W, Kasper M, Hofer S, Plachky J, Grone HJ, Kurschus FC, Schmidt AM, Yan SD, Martin E, Schleicher E, Stern DM, Hammerling GG, Nawroth PP, Arnold B. 2004. Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response. J Clin Invest 113:1641-1650. https://doi.org/10.1172/JCI200418704.
20. Lutterloh EC, Opal SM, Pittman DD, Keith JC, Jr, Tan XY, Clancy BM, Palmer H, Milarski K, Sun Y, Palardy JE, Parejo NA, Kessimian N. 2007. Inhibition of the RAGE products increases survival in experimental models of severe sepsis and systemic infection. Crit Care 11:R122. https:// doi.org/10.1186/cc6184.
21. Achouiti A, de Vos AF, de Beer R, Florquin S, van't Veer C, van der Poll T. 2013. Limited role of the receptor for advanced glycation end products during Streptococcus pneumoniae bacteremia. J Innate Immun 5:603- 612. https://doi.org/10.1159/000348739.
22. Vincent JL, Rello J, Marshall J, Silva E, Anzueto A, Martin CD, Moreno R, Lipman J, Gomersall C, Sakr Y, Reinhart K. 2009. International study of the prevalence and outcomes of infection in intensive care units. JAMA 302:2323-2329. https://doi.org/10.1001/jama.2009.1754.
23. Giamarellou H, Antoniadou A, Kanellakopoulou K. 2008. Acinetobacter baumannii: a universal threat to public health? Int J Antimicrob Agents 32:106 -119. https://doi.org/10.1016/j.ijantimicag.2008.02.013.
24. Grgurich PE, Hudcova J, Lei Y, Sarwar A, Craven DE. 2012. Management and prevention of ventilator-associated pneumonia caused by multidrugresistant pathogens. Expert Rev Respir Med 6:533-555. https://doi.org/ 10.1586/ers.12.45.
25. Trottier V, Segura PG, Namias N, King D, Pizano LR, Schulman CI. 2007. Outcomes of Acinetobacter baumannii infection in critically ill burned patients. J Burn Care Res 28:248 -254. https://doi.org/10.1097/ BCR.0B013E318031A20F.
26. Falagas ME, Bliziotis IA. 2007. Pandrug-resistant Gram-negative bacteria: the dawn of the post-antibiotic era? Int J Antimicrob Agents 29: 630-636. https://doi.org/10.1016/j.ijantimicag.2006.12.012.
27. Brett J, Schmidt AM, Yan SD, Zou YS, Weidman E, Pinsky D, Nowygrod R, Neeper M, Przysiecki C, Shaw A, Migheli A, Stern D. 1993. Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. Am J Pathol 143:1699 -1712.
28. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB.Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 39:309 -317. https://doi.org/10.1086/421946.
29. Howard M, Muchamuel T, Andrade S, Menon S. 1993. Interleukin 10 protects mice from lethal endotoxemia. J Exp Med 177:1205-1208. https://doi.org/10.1084/jem.177.4.1205.
30. Derkx B, Marchant A, Goldman M, Bijlmer R, van Deventer S. 1995. High levels of interleukin-10 during the initial phase of fulminant meningococcal septic shock. J Infect Dis 171:229 -232. https://doi.org/10.1093/ infdis/171.1.229.
31. Spellberg B, Bartlett JG, Gilbert DN. 2013. The future of antibiotics and resistance. N Engl J Med 368:299 -302. https://doi.org/10.1056/ NEJMp1215093.
32. Czaplewski L, Bax R, Clokie M, Dawson M, Fairhead H, Fischetti VA, Foster S, Gilmore BF, Hancock RE, Harper D, Henderson IR, Hilpert K, Jones BV, Kadioglu A, Knowles D, Olafsdottir S, Payne D, Projan S, Shaunak S, Silverman J, Thomas CM, Trust TJ, Warn P, Rex JH. 2016. Alternatives to antibiotics-a pipeline portfolio review. Lancet Infect Dis 16:239 -251. https://doi.org/10.1016/S1473-3099(15)00466-1.
33. Reynolds PR, Schmitt RE, Kasteler SD, Sturrock A, Sanders K, Bierhaus A, Nawroth PP, Paine R, III, Hoidal JR. 2010. Receptors for advanced glycation end-products targeting protect against hyperoxia-induced lung injury in mice. Am J Respir Cell Mol Biol 42:545-551. https://doi.org/ 10.1165/rcmb.2008-0265OC.
34. Milutinovic PS, Alcorn JF, Englert JM, Crum LT, Oury TD. 2012. The receptor for advanced glycation end products is a central mediator of asthma pathogenesis. Am J Pathol 181:1215-1225. https://doi.org/ 10.1016/j.ajpath.2012.06.031.
35. Englert JM, Hanford LE, Kaminski N, Tobolewski JM, Tan RJ, Fattman CL, Ramsgaard L, Richards TJ, Loutaev I, Nawroth PP, Kasper M, Bierhaus A, Oury TD. 2008. A role for the receptor for advanced glycation end products in idiopathic pulmonary fibrosis. Am J Pathol 172:583-591. https://doi.org/10.2353/ajpath.2008.070569.
36. Yamamoto Y, Harashima A, Saito H, Tsuneyama K, Munesue S, Motoyoshi S, Han D, Watanabe T, Asano M, Takasawa S, Okamoto H, Shimura S, Karasawa T, Yonekura H, Yamamoto H. 2011. Septic shock is associated with receptor for advanced glycation end products ligation of LPS. J Immunol 186:3248 -3257. https://doi.org/10.4049/jimmunol.1002253.
37. Chen Y, Akirav EM, Chen W, Henegariu O, Moser B, Desai D, Shen JM, Webster JC, Andrews RC, Mjalli AM, Rothlein R, Schmidt AM, Clynes R, Herold KC. 2008. RAGE ligation affects T cell activation and controls T cell differentiation. J Immunol 181:4272- 4278. https://doi.org/10.4049/ jimmunol.181.6.4272.
38. Raman KG, Sappington PL, Yang R, Levy RM, Prince JM, Liu S, Watkins SK, Schmidt AM, Billiar TR, Fink MP. 2006. The role of RAGE in the pathogenesis of intestinal barrier dysfunction after hemorrhagic shock. Am J Physiol Gastrointest Liver Physiol 291:G556 -G565. https://doi.org/ 10.1152/ajpgi.00055.2006.
39. Weber DJ, Gracon AS, Ripsch MS, Fisher AJ, Cheon BM, Pandya PH, Vittal R, Capitano ML, Kim Y, Allette YM, Riley AA, McCarthy BP, Territo PR, Hutchins GD, Broxmeyer HE, Sandusky GE, White FA, Wilkes DS. 2014. The HMGB1-RAGE axis mediates traumatic brain injury-induced pulmonary dysfunction in lung transplantation. Sci Transl Med 6:252ra124. https://doi.org/10.1126/scitranslmed.3009443.
40. Song F, Hurtado del Pozo C, Rosario R, Zou YS, Ananthakrishnan R, Xu X, Patel PR, Benoit VM, Yan SF, Li H, Friedman RA, Kim JK, Ramasamy R, Ferrante AW, Jr, Schmidt AM. 2014. RAGE regulates the metabolic and inflammatory response to high-fat feeding in mice. Diabetes 63: 1948-1965. https://doi.org/10.2337/db13-1636.
41. Zanotti S, Kumar A, Kumar A. 2002. Cytokine modulation in sepsis and septic shock. Expert Opin Investig Drugs 11:1061-1075. https://doi.org/ 10.1517/13543784.11.8.1061.
42. Schmidt AM, Vianna M, Gerlach M, Brett J, Ryan J, Kao J, Esposito C, Hegarty H, Hurley W, Clauss M, Wang F, Pan Y, Tsang T, Stern D. 1992. Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface. J Biol Chem 267:14987-14997.
43. Constien R, Forde A, Liliensiek B, Grone HJ, Nawroth P, Hammerling G, Arnold B. 2001. Characterization of a novel EGFP reporter mouse to monitor Cre recombination as demonstrated by a Tie2 Cre mouse line. Genesis 30:36-44. https://doi.org/10.1002/gene.1030.
44. Jacobs AC, Hood I, Boyd KL, Olson PD, Morrison JM, Carson S, Sayood K, Iwen PC, Skaar EP, Dunman PM. 2010. Inactivation of phospholipase D diminishes Acinetobacter baumannii pathogenesis. Infect Immun 78: 1952-1962. https://doi.org/10.1128/IAI.00889-09.
45. Moore JL, Becker KW, Nicklay JJ, Boyd KL, Skaar EP, Caprioli RM. 24 July 2013. Imaging mass spectrometry for assessing temporal proteomics: analysis of calprotectin in Acinetobacter baumannii pulmonary infection. Proteomics https://doi.org/10.1002/pmic.201300046.
46. Hood MI, Mortensen BL, Moore JL, Zhang Y, Kehl-Fie TE, Sugitani N, Chazin WJ, Caprioli RM, Skaar EP. 2012. Identification of an Acinetobacter baumannii zinc acquisition system that facilitates resistance to calprotectin-mediated zinc sequestration. PLoS Pathog 8:e1003068. https://doi.org/10.1371/journal.ppat.1003068.
47. Hood MI, Becker KW, Roux CM, Dunman PM, Skaar EP. 2013. Genetic determinants of intrinsic colistin tolerance in Acinetobacter baumannii. Infect Immun 81:542-551. https://doi.org/10.1128/IAI.00704-12.
48. Hood MI, Uzhachenko R, Boyd K, Skaar EP, Ivanova AV. 2013. Loss of mitochondrial protein Fus1 augments host resistance to Acinetobacter baumannii infection. Infect Immun 81:4461- 4469. https://doi.org/ 10.1128/IAI.00771-13.
49. Mortensen BL, Rathi S, Chazin WJ, Skaar EP. 2014. Acinetobacter baumannii response to host-mediated zinc limitation requires the transcriptional regulator Zur. J Bacteriol 196:2616 -2626. https://doi.org/10.1128/ JB.01650-14.
50. Noto MJ, Boyd KL, Burns WJ, Varga MG, Peek RM, Jr, Skaar EP. 2015. Toll-like receptor 9 contributes to defense against Acinetobacter baumannii infection. Infect Immun 83:4134-4141. https://doi.org/10.1128/ IAI.00410-15.